Discovery and bioactivity of 4-(2-arylpyrido[3′,2′:3,4] pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 1, 2012, Pages 339-342

  Wang, Jia ^a   Wang, Xiang ^a   Chen, Yanhong ^a   Chen, Simeng ^a   Chen, Guang ^a   Tong, Linjiang ^a   Meng, Linghua ^a   Xie, Yuyuan ^a   Ding, Jian ^a   Yang, Chunhao ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cancer; PI 103 analogs; PI3K

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 (2 ARYLPYRIDO[3',2':3,4]PYRROLO[1,2 F][1,2,4]TRIAZIN 4 YL)MORPHOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; ONCOGENE SRC; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FURANS; HUMANS; INHIBITORY CONCENTRATION 50; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; PYRIMIDINES;

EID: 84655164332     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.003     Document Type: Article

References (12)

1. B. Vanhaesebroeck, S.J. Leevers, G. Panayotou, and M.D. Waterfield Trends Biochem. Sci. 22 1997 267
2. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, G.J. Riggins, J.K.V. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Science 304 2004 554
3. V. Stambolic, A. Suzuki, J.L. de la Pompa, G.M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J.M. Penninger, D.P. Siderovski, and T.W. Mak Cell 95 1998 29
4. F. Vazquez, and W.R. Sellers Biochim. Biophys. Acta 1470 2000 M21
5. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Nat. Rev. Drug Disc. 8 2009 627
6. A.G. Bader, S. Kang, L. Zhao, and P.K. Vogt Nat. Rev. Cancer 5 2005 921
7. D.P. Sutherlin, D. Sampath, M. Berry, G. Castanedo, Z. Chang, I. Chuckowree, J. Dotson, A. Folkes, L. Friedman, R. Goldsmith, T. Heffron, L. Lee, J. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, W.W. Prior, L. Salphati, S. Sideris, Q. Tian, V. Tsui, N.C. Wan, S. Wang, C. Wiesmann, S. Wong, and B.-Y. Zhu J. Med. Chem. 53 2010 1086
8. N.D.D. Angelo, T.-S. Kim, K. Andrews, S.K. Booker, S. Caenepeel, K. Chen, D.D. Amico, D. Freeman, J. Jiang, L. Liu, J.D. McCarter, T. San Miguel, E.L. Mullady, M. Schrag, R. Subramanian, J. Tang, R.C. Wahl, L. Wang, D.A. Whittington, T. Wu, N. Xi, Y. Xu, P. Yakowec, K. Yang, L.P. Zalameda, N. Zhang, P. Hughes, and M.H. Norman J. Med. Chem. 54 2011 1789
9. D. Kong, and T. Yamori Curr. Med. Chem. 16 2009 2839
10. J. Ohwada, H. Ebiike, H. Kawada, M. Tsukazaki, M. Nakamura, T. Miyazaki, K. Morikami, K. Yoshinari, M. Yoshida, O. Kondoh, S. Kuramoto, K. Ogawa, Y. Aoki, and N. Shimma Bioorg. Med. Chem. Lett. 21 2011 1767
11. Bradley, S. E.; Krulle, T. M.; Murray, P. J.; Procter, M. J.; Rowley, R. J.; Sambrook Smith, C. P.; Thomas, G. H. U.S. Patent 2005261272A1.
12. F.I. Raynaud, S. Eccles, P.A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. Di-Stefano, Z. Ahmad, S. Guillard, L.M. Bjerke, L. Kelland, M. Valenti, L. Patterson, S. Gowan, A. de Haven Brandon, M. Hayakawa, H. Kaizawa, T. Koizumi, T. Ohishi, S. Patel, N. Saghir, P. Parker, M. Waterfield, and P. Workman Cancer Res. 67 2007 5840